Purpose and objective(s)
The COVID-19 pandemic challenges available hospital capacity. This is augmented by absenteeism of healthcare workers (HCW). Strategies to protect HCW are desperately needed. Bacille Calmette-Guérin (BCG) has protective non-specific effects against other infections; a plausible immunological mechanism is identified in terms of “trained innate immunity”. European and North American trials to study if BCG can reduce the incidence and/or severity of COVID-19 have now been initiated. African studies are needed.
The underlying hypothesis for this study is that BCG vaccination of HCW reduces unplanned absenteeism due to illness of HCW by 20%.
The primary objective of the study is to reduce unplanned absenteeism due to illness among HCW during the COVID-19 pandemic. Secondary aims are to reduce the number of HCW with COVID-19, reduce hospital admissions of HCW during the COVID-19 pandemic and improving capacity for clinical research in Cape Verde and Guinea-Bissau.
See the research teams here.